<p>迷幻市场价值预计在未来几年将增长约三倍。虽然绝对规模不大，但这种增长潜力将创造许多赢家股票。</p>
<p>迷幻药物继续主要用于治疗用途。它们对疼痛障碍具有深刻的疗效，特别在治疗抑郁症和其他心理健康障碍方面非常有用。</p>
<p>作为一组，迷幻药物包括传统上与幻觉和其他副作用相关联的 LSD 等药物，这使它们被认为具有危险性。然而，它们在治疗难治性抑郁症、恐慌障碍和阿片类药物成瘾方面的潜在疗效使它们具有商业价值。</p>
<p>长期以来，娱乐用户一直支持迷幻药物受到过度批评，并在治疗心理健康障碍方面具有实际效用的观念。制药行业开始接受这种观念，开辟了新的治疗途径和机会。在这个过程中，对于愿意早期介入的人来说，投资迷幻股票的机会正在出现。</p>
<h2>Mind Medicine（MNMD）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Daniel Patrick Martin / Shutterstock.com</p>
<p><strong>Mind Medicine</strong>（纳斯达克：<strong>MNMD</strong>）的主力候选药物是 MM120，这是一种优化的 LSD 形式，用于治疗广泛性焦虑障碍。 LSD 和其他迷幻药物（如 MDMA）在治疗与压力有关的障碍方面的潜在用途之一是该股受到如此多关注的原因。</p>
<p>然而，迷幻药物和迷幻股票的世界仍然是非常不确定的领域。很大一部分机会取决于监管批准。FDA 最近就 MDMA 用于创伤后应激障碍的非约束性裁决引起了一些担忧。尽管 Mind Medicine 使用的是 LSD 而不是 MDMA，但这一消息仍使 Mind Medicine 的股价下跌。</p>
<p>FDA 继续认可 MDM、LSD 和其他迷幻药物的治疗潜力。预计 Mind Medicine 仍将在今年下半年启动 MM120 的 3 期临床试验。与此同时，该公司还计划同时启动其他研究，研究 MDMA 衍生物用于自闭症的治疗。</p>
<h2>GH Research（GHRS）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Sisacorn / Shutterstock.com</p>
<p><strong>GH Research</strong>（纳斯达克：<strong>GHRS</strong>）股票代表一家致力于开发各种治疗精神疾病和神经疾病的疗法的公司。该公司特别专注于开发 DMT，用于治疗治疗难治性抑郁症（TRD）的患者。</p>
<p>GH Research 正在研究的 DMT 特定变体可以在几种植物物种以及某些蟾蜍物种中自然发现。</p>
<p>无论如何，GH Research 股票在 2024 年表现非常出色，年初至今翻了一番多。这一成功使股价在撰写时达到 12 美元。仍然有很大潜力，共识目标价高于 36 美元。</p>
<p>该公司用于治疗 mebufotenin（5-MeO-DMT）吸入剂的 2b 期试验非常成功，预计将于今年下半年结束。</p>
<p>同一药物正在进行用于产后抑郁症治疗的 2a 期试验。该公司的现金储备可支持到 2026 年。这些最近的持续成功，加上资金支持，使 GH Research 成为值得关注的顶级迷幻股票之一。</p>
<h2>Atai Life Sciences（ATAI）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Billion Photos / Shutterstock</p>
<p><strong>Atai Life Sciences</strong>（纳斯达克：<strong>ATAI</strong>）是另一家受到最近 FDA 关于 MDMA 用于创伤后应激障碍决定打击的公司。股价在这一消息公布后下跌了超过 10%，并持续走低。</p>
<p>该 FDA 决定是在 6 月 4 日作出的。该公司继续收集关于治疗难治性抑郁症的短期迷幻疗法的数据。Atai Life Sciences 最近还宣布进一步进行溴酚菌素研究，用于治疗重性抑郁症（MDD）。</p>
<p>该试验利用溴酚菌素的活性代谢物 psilocin，以实现两小时的较短治疗时间。该公司已经为此目的专利了 psilocin，命名为 ELE-101。</p>
<p>重要的是要记住，最近 FDA 的决定涉及 MDMA 而不是溴酚菌素。此外，它特别针对 MDMA 在治疗创伤后应激障碍方面的使用。溴酚菌素及其代谢物不受该决定影响，并且 Atai Life Sciences 正在研究其在 PTSD 之外的其他用途。</p>
<p>_在本文发布日期，Alex Sirois 对提及的证券没有（直接或间接）任何持仓。本文中表达的观点属于作者个人，遵守 InvestorPlace.com 的发布指南。</p>
<p><em>在本文发布日期，负责编辑对提及的证券没有（直接或间接）任何持仓。</em></p>
<p>Alex Sirois 是 InvestorPlace 的自由撰稿人，他的个人股票投资风格侧重于长期持有、积累财富的股票选择。他曾在从电子商务到翻译再到教育等多个行业工作，并利用他在乔治华盛顿大学获得的工商管理硕士学位，通过这些技能过滤他的写作。</p>

GHRS

<p>预计迷幻市场价值将翻三倍，为投资迷幻股票创造机会。Mind Medicine、GH Research 和 Atai Life Sciences 等公司正在开发利用 LSD 和 DMT 等迷幻物质治疗心理健康障碍的疗法。这些股票在临床试验中表现出有希望的结果，并具有显著增长潜力</p>

<p>The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning stocks.</p>
<div class="lb-trans"><p>迷幻市场价值预计在未来几年将增长约三倍。虽然绝对规模不大，但这种增长潜力将创造许多赢家股票。</p>
</div><p>Psychedelics continue to be developed primarily for their therapeutic uses. They have deep efficacy for pain disorders and are especially useful in treating depression and other mental health disorders.</p>
<div class="lb-trans"><p>迷幻药物继续主要用于治疗用途。它们对疼痛障碍具有深刻的疗效，特别在治疗抑郁症和其他心理健康障碍方面非常有用。</p>
</div><p>As a group, psychedelics include drugs such as LSD that have traditionally been associated with hallucinations and other side effects that have given them a dangerous perception. However, their potential efficacy in treating resistant depression, panic disorders and opiate addiction makes them commercially valuable.</p>
<div class="lb-trans"><p>作为一组，迷幻药物包括传统上与幻觉和其他副作用相关联的 LSD 等药物，这使它们被认为具有危险性。然而，它们在治疗难治性抑郁症、恐慌障碍和阿片类药物成瘾方面的潜在疗效使它们具有商业价值。</p>
</div><p>Recreational users have long supported the idea that psychedelics are much maligned and have real utility in treating mental health disorders. The pharmaceutical industry is beginning to get on board with that notion, opening new treatment pathways and opportunities overall. In the process, opportunities to invest in psychedelic stocks are emerging for those willing to get in early.</p>
<div class="lb-trans"><p>长期以来，娱乐用户一直支持迷幻药物受到过度批评，并在治疗心理健康障碍方面具有实际效用的观念。制药行业开始接受这种观念，开辟了新的治疗途径和机会。在这个过程中，对于愿意早期介入的人来说，投资迷幻股票的机会正在出现。</p>
</div><h2>Mind Medicine (MNMD)</h2>
<div class="lb-trans"><h2>Mind Medicine（MNMD）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Daniel Patrick Martin / Shutterstock.com</p>
<div class="lb-trans"><p>来源：Daniel Patrick Martin / Shutterstock.com</p>
</div><p><strong>Mind Medicine’s</strong> (NASDAQ:<strong>MNMD</strong>) lead candidate is MM120, an optimized form of LSD used to treat generalized anxiety disorder. The potential utility of LSD and other psychedelics, such as MDMA, in the treatment of stress-related disorders is one of the reasons the stock is receiving so much attention.</p>
<div class="lb-trans"><p><strong>Mind Medicine</strong>（纳斯达克：<strong>MNMD</strong>）的主力候选药物是 MM120，这是一种优化的 LSD 形式，用于治疗广泛性焦虑障碍。 LSD 和其他迷幻药物（如 MDMA）在治疗与压力有关的障碍方面的潜在用途之一是该股受到如此多关注的原因。</p>
</div><p>However, the world of psychedelics and psychedelics stocks is still very much Wild West territory. A lot of the opportunity hinges upon regulatory approval. Recent non-binding judgments by the FDA related to the use of MDMA for post-traumatic stress disorder are causing some concern. While Mind Medicine utilizes LSD and not MDMA, the news still sent Mind Medicine’s shares lower.</p>
<div class="lb-trans"><p>然而，迷幻药物和迷幻股票的世界仍然是非常不确定的领域。很大一部分机会取决于监管批准。FDA 最近就 MDMA 用于创伤后应激障碍的非约束性裁决引起了一些担忧。尽管 Mind Medicine 使用的是 LSD 而不是 MDMA，但这一消息仍使 Mind Medicine 的股价下跌。</p>
</div><p>The FDA continues to recognize the therapeutic potential of MDM, LSD and other psychedelics. Mind Medicine is still expected to initiate a Phase 3 clinical trial for MM120 in the second half of this year. Meanwhile, the company is concurrently planning to initiate other studies of MDMA derivatives for the treatment of autism.</p>
<div class="lb-trans"><p>FDA 继续认可 MDM、LSD 和其他迷幻药物的治疗潜力。预计 Mind Medicine 仍将在今年下半年启动 MM120 的 3 期临床试验。与此同时，该公司还计划同时启动其他研究，研究 MDMA 衍生物用于自闭症的治疗。</p>
</div><h2>GH Research (GHRS)</h2>
<div class="lb-trans"><h2>GH Research（GHRS）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Sisacorn / Shutterstock.com</p>
<div class="lb-trans"><p>来源：Sisacorn / Shutterstock.com</p>
</div><p><strong>GH Research</strong> (NASDAQ:<strong>GHRS</strong>) stock represents a company engaged in the development of various therapies to treat psychiatric and neurological disorders. The company is especially focused on the development of DMT for use in treating patients with treatment-resistant depression (TRD).</p>
<div class="lb-trans"><p><strong>GH Research</strong>（纳斯达克：<strong>GHRS</strong>）股票代表一家致力于开发各种治疗精神疾病和神经疾病的疗法的公司。该公司特别专注于开发 DMT，用于治疗治疗难治性抑郁症（TRD）的患者。</p>
</div><p>The particular variant of DMT that GH research is studying can be found naturally in several species of plants as well as certain toad species.</p>
<div class="lb-trans"><p>GH Research 正在研究的 DMT 特定变体可以在几种植物物种以及某些蟾蜍物种中自然发现。</p>
</div><p>Anyway, GH research stock has done extraordinarily well in 2024, more than doubling year-to-date. That success has brought share prices to $12 at the time of writing. Plenty of potential remains, with a consensus target price above $36.</p>
<div class="lb-trans"><p>无论如何，GH Research 股票在 2024 年表现非常出色，年初至今翻了一番多。这一成功使股价在撰写时达到 12 美元。仍然有很大潜力，共识目标价高于 36 美元。</p>
</div><p>The company’s phase 2b trial for a mebufotenin (5-MeO-DMT) inhalant has been very successful and is expected to end in the second half of this year.</p>
<div class="lb-trans"><p>该公司用于治疗 mebufotenin（5-MeO-DMT）吸入剂的 2b 期试验非常成功，预计将于今年下半年结束。</p>
</div><p>That same drug is being tested in a phase 2a trial for the treatment of postpartum depression. The company has a cash runway into 2026. That funding, combined with those recent ongoing successes, makes GH Research one of the top psychedelic stocks to watch.</p>
<div class="lb-trans"><p>同一药物正在进行用于产后抑郁症治疗的 2a 期试验。该公司的现金储备可支持到 2026 年。这些最近的持续成功，加上资金支持，使 GH Research 成为值得关注的顶级迷幻股票之一。</p>
</div><h2>Atai Life Sciences (ATAI)</h2>
<div class="lb-trans"><h2>Atai Life Sciences（ATAI）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Billion Photos / Shutterstock</p>
<div class="lb-trans"><p>来源：Billion Photos / Shutterstock</p>
</div><p><strong>Atai Life Sciences</strong> (NASDAQ:<strong>ATAI</strong>) is another stock that was hit hard by the recent FDA decision on MDMA for PTSD. Shares fell more than 10% in the wake of the news and have continued downward since.</p>
<div class="lb-trans"><p><strong>Atai Life Sciences</strong>（纳斯达克：<strong>ATAI</strong>）是另一家受到最近 FDA 关于 MDMA 用于创伤后应激障碍决定打击的公司。股价在这一消息公布后下跌了超过 10%，并持续走低。</p>
</div><p>That FDA decision fell on June 4. The company continues to collect data on short-term psychedelic therapies for treatment-resistant depression. Atai Life Sciences also recently announced further ongoing studies of psilocybin for the treatment of major depressive disorder (MDD).</p>
<div class="lb-trans"><p>该 FDA 决定是在 6 月 4 日作出的。该公司继续收集关于治疗难治性抑郁症的短期迷幻疗法的数据。Atai Life Sciences 最近还宣布进一步进行溴酚菌素研究，用于治疗重性抑郁症（MDD）。</p>
</div><p>That trial utilizes psilocin, the active metabolite of psilocybin in order to affect a shorter treatment duration of two hours. The company has patented psilocin for that purpose under the name ELE-101.</p>
<div class="lb-trans"><p>该试验利用溴酚菌素的活性代谢物 psilocin，以实现两小时的较短治疗时间。该公司已经为此目的专利了 psilocin，命名为 ELE-101。</p>
</div><p>It’s important to remember that the recent FDA decision related to MDMA and not psilocybin. Furthermore, it was specifically for the use of MDMA in the treatment of PTSD. Psilocybin and its metabolites are unaffected by the decision and are being studied for other purposes outside of PTSD by Atai Life Sciences.</p>
<div class="lb-trans"><p>重要的是要记住，最近 FDA 的决定涉及 MDMA 而不是溴酚菌素。此外，它特别针对 MDMA 在治疗创伤后应激障碍方面的使用。溴酚菌素及其代谢物不受该决定影响，并且 Atai Life Sciences 正在研究其在 PTSD 之外的其他用途。</p>
</div><p><em>On the date of publication, Alex Sirois did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em> <em>Publishing Guidelines.</em></p>
<div class="lb-trans"><p>_在本文发布日期，Alex Sirois 对提及的证券没有（直接或间接）任何持仓。本文中表达的观点属于作者个人，遵守 InvestorPlace.com 的发布指南。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p><em>在本文发布日期，负责编辑对提及的证券没有（直接或间接）任何持仓。</em></p>
</div><p>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</p>
<div class="lb-trans"><p>Alex Sirois 是 InvestorPlace 的自由撰稿人，他的个人股票投资风格侧重于长期持有、积累财富的股票选择。他曾在从电子商务到翻译再到教育等多个行业工作，并利用他在乔治华盛顿大学获得的工商管理硕士学位，通过这些技能过滤他的写作。</p>
</div>

3 只迷幻药股票飞向月球及更远